Tolerability of a Novel Spectacle Design With Reduced Peripheral Contrast
Launched by SIGHTGLASS VISION, INC. · Nov 30, 2018
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
This feasibility study was conducted to assess the performance of three experimental spectacle lens designs (spectacle lenses) in children between 6 and 9 years of age with myopia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ages between 6 and 12 years
- • Myopia between -1.00 and -4.00 D
- Exclusion Criteria:
- • Participating in any clinical or other research study
- • Contact lens wearer
About Sightglass Vision, Inc.
SightGlass Vision, Inc. is a pioneering clinical trial sponsor dedicated to advancing innovative solutions for the treatment of myopia and other vision-related conditions. With a focus on developing cutting-edge optical devices and therapies, the company is committed to enhancing patient outcomes through rigorous research and evidence-based practices. Leveraging a team of experienced professionals and a robust clinical development framework, SightGlass Vision aims to bring transformative products to market that address the growing global challenge of myopia, ultimately improving the quality of life for individuals affected by vision impairments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Waterloo, Ontario, Canada
Patients applied
Trial Officials
Joe Rappon, OD, MS
Study Director
SightGlass Vision
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials